Nebenwirkungen · Aimovig
Aimovig 70 mg solution for injection in pre-filled syringe Aimovig 140 mg solution for injection in pre-filled syringe Aimovig 70 mg solution for injection in pre-filled pen Aimovig 140 mg solution for injection in pre-filled pen · Abschnitt 4.8 · PDF-Seite 6
HOS-139258 · Präparat HOS-098306
Cutaneous and hypersensitivity reactions In the integrated 12-week placebo-controlled phase of the studies, non-serious cases of rash, pruritus and swelling/oedema were observed, which in the majority of cases were mild and did not lead to treatment discontinuation.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-12-01T16:50:00Z · SHA-256 3eca639638392984c39621d5f5973e846e56d13ded09a7d8628d6a71c4e0ca87 · Passage 67d2b649ea8f472e33a0f966a75cda54ac47f45ddc491adbb8e02c67d978bf50 · Zeichen 3397–3663 im Abschnitt